{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:01Z","timestamp":1785131941504,"version":"3.55.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03301-x","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:12:30Z","timestamp":1782472350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chromatin chronicles: Unlocking the therapeutic potential of histone modifiers in hepatocellular carcinoma"],"prefix":"10.1007","volume":"43","author":[{"given":"Muhammad","family":"Sulaiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umm E.","family":"Hani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Mulumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengtao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"4","key":"3301_CR1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s10620-019-05537-2","volume":"64","author":"M Sayiner","year":"2019","unstructured":"Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: a global perspective. Dig Dis Sci. 2019;64(4):910\u20137.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"3301_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, Kumar M, Eslam M, George J, Mahtab MA, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2020;5(2):167\u2013228.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6648","key":"3301_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/38444","volume":"389","author":"K Luger","year":"1997","unstructured":"Luger K, M\u00e4der AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nat. 1997;389(6648):251\u201360.","journal-title":"Nat"},{"issue":"5","key":"3301_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1073\/pnas.51.5.786","volume":"51","author":"VG Allfrey","year":"1964","unstructured":"Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of rna synthesis. Proc Natl Acad Sci U S A. 1964;51(5):786\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3301_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ng.154","volume":"40","author":"Z Wang","year":"2008","unstructured":"Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40(7):897\u2013903.","journal-title":"Nat Genet"},{"issue":"7","key":"3301_CR6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-22-0784","volume":"29","author":"G Micevic","year":"2023","unstructured":"Micevic G, Bosenberg MW, Yan Q. The crossroads of cancer epigenetics and immune checkpoint therapy. Clin Cancer Res. 2023;29(7):1173\u201382.","journal-title":"Clin Cancer Res"},{"key":"3301_CR7","doi-asserted-by":"crossref","unstructured":"Farrokhi Yekta R, Farahani M, Koushki M, Amiri-Dashatan N. Deciphering the potential role of post-translational modifications of histones in gastrointestinal cancers: a proteomics-based review with therapeutic challenges and opportunities. Front Oncol. 2024 [cited 2025 Dec 18]:[14]. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2024.1481426\/full","DOI":"10.3389\/fonc.2024.1481426"},{"issue":"11","key":"3301_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/metabo11110792","volume":"11","author":"J King","year":"2021","unstructured":"King J, Patel M, Chandrasekaran S. Metabolism, HDACs, and HDAC inhibitors: a systems biology perspective. Metabolites. 2021;11(11):792.","journal-title":"Metabolites"},{"issue":"10","key":"3301_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2025.101556","volume":"19","author":"L Liu","year":"2025","unstructured":"Liu L, Mo Z, Qin N, Pi J, Mao L, Deng G, et al. Hepatocyte apolipoprotein j accelerates injury-induced liver fibrosis by activation signal transducer and activator of transcription 3 through ranbp2 mediated-SUMOylation. Cell Mol Gastroenterol Hepatol. 2025;19(10):101556.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"3301_CR10","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.3892\/or.2015.4205","volume":"34","author":"J Liu","year":"2015","unstructured":"Liu J, Wu W, Jin J. A novel mutation in SIRT1-AS leading to a decreased risk of HCC. Oncol Rep. 2015;34(5):2343\u201350.","journal-title":"Oncol Rep"},{"issue":"1","key":"3301_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/1673-5374.375315","volume":"19","author":"N Sola-Sevilla","year":"2024","unstructured":"Sola-Sevilla N, Puerta E. SIRT2 as a potential new therapeutic target for alzheimer\u2019s disease. Neural Regen Res. 2024;19(1):124.","journal-title":"Neural Regen Res"},{"issue":"4","key":"3301_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/biology13040216","volume":"13","author":"W Abumustafa","year":"2024","unstructured":"Abumustafa W, Castven D, Sharif-Askari FS, Abi Zamer B, Hamad M, Marquardt JU, et al. PRMT5 mediated HIF1\u03b1 signaling and ras-related nuclear protein as promising biomarker in hepatocellular carcinoma. Biology. 2024;13(4):216.","journal-title":"Biology"},{"key":"3301_CR13","doi-asserted-by":"crossref","unstructured":"Wang X, Liu W, Zhan C, Zhang Y, Li X, Wang Y, et al. Alternative splicing of EZH2 regulated by SNRPB mediates hepatocellular carcinoma progression via BMP2 signaling pathway. iScience. 2025 [cited 2025 Feb 13] [28(1)]. Available from: https:\/\/www.cell.com\/iscience\/abstract\/S2589-0042(24)02853-0","DOI":"10.1016\/j.isci.2024.111626"},{"issue":"1","key":"3301_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ymthe.2022.09.019","volume":"31","author":"YB Yang","year":"2023","unstructured":"Yang YB, Wu CY, Wang XY, Deng J, Cao WJ, Tang YZ, et al. Targeting inflammatory macrophages rebuilds therapeutic efficacy of DOT1L inhibition in hepatocellular carcinoma. Mol Ther. 2023;31(1):105\u201318.","journal-title":"Mol Ther"},{"issue":"26","key":"3301_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.omtn.2021.10.028","volume":"3","author":"W Liang","year":"2021","unstructured":"Liang W, Shi C, Hong W, Li P, Zhou X, Fu W, et al. Super-enhancer-driven lncRNA-DAW promotes liver cancer cell proliferation through activation of Wnt\/\u03b2-catenin pathway. Mol Ther Nucleic Acids. 2021;3(26):1351\u201363.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"3301_CR16","first-page":"9757","volume":"15","author":"J Qin","year":"2018","unstructured":"Qin J, Li Q, Zeng Z, Wu P, Jiang Y, Luo T, et al. Increased expression of G9A contributes to carcinogenesis and indicates poor prognosis in hepatocellular carcinoma. Oncol Lett. 2018;15(6):9757\u201365.","journal-title":"Oncol Lett"},{"issue":"2","key":"3301_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115250","volume":"44","author":"L Ye","year":"2025","unstructured":"Ye L, Shen S, Mao Q, Lu H, Liu H, Zhang P, et al. Nuclear-localized HKDC1 promotes hepatocellular carcinoma through phosphorylating RBBP5 to upregulate H3K4me3. Cell Rep. 2025;44(2):115250.","journal-title":"Cell Rep"},{"issue":"7","key":"3301_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941\u201353.","journal-title":"Cell"},{"issue":"1","key":"3301_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s42764-023-00118-0","volume":"5","author":"L Di","year":"2024","unstructured":"Di L, Zhu WG. The role of H3K27me3 methylation in cancer development. Genome Instab Dis. 2024;5(1):17\u201334.","journal-title":"Genome Instab Dis"},{"issue":"1","key":"3301_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/epigenomes1010004","volume":"1","author":"G Verde","year":"2017","unstructured":"Verde G, Querol-Pa\u00f1os J, Cebri\u00e0-Costa JP, Pascual-Reguant L, Serra-Bardenys G, Iturbide A, et al. Lysine-specific histone demethylases contribute to cellular differentiation and carcinogenesis. Epigenomes. 2017;1(1):4.","journal-title":"Epigenomes"},{"key":"3301_CR21","doi-asserted-by":"crossref","unstructured":"Lv S, Zhao X, Zhang E, Yan Y, Ma X, Li N, et al. Lysine demethylase KDM1A promotes cell growth via FKBP8\u2013BCL2 axis in hepatocellular carcinoma. J Biol Chem. 2022 [cited 2025 Feb 18]:[298(9)]. Available from: https:\/\/www.jbc.org\/article\/S0021-9258(22)00817-1\/abstract","DOI":"10.1016\/j.jbc.2022.102374"},{"issue":"20","key":"3301_CR22","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1080\/15384101.2021.1962632","volume":"20","author":"X Huang","year":"2021","unstructured":"Huang X, Pan J, Wang G, Huang T, Li C, Wang Y, et al. UNC5B-AS1 promotes the proliferation, migration and EMT of hepatocellular carcinoma cells via regulating miR-4306\/KDM2A axis. Cell Cycle. 2021;20(20):2114\u201324.","journal-title":"Cell Cycle"},{"key":"3301_CR23","doi-asserted-by":"crossref","unstructured":"Zhu Z yi, Tang N, Wang M fu, Zhou J chao, Wang J lin, Ren H zhen, et al. Comprehensive pan-cancer genomic analysis reveals phf19 as a carcinogenic indicator related to immune infiltration and prognosis of hepatocellular carcinoma. Front Immunol. 2022 [cited 2025 Feb 18]:[12]. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2021.781087\/full","DOI":"10.3389\/fimmu.2021.781087"},{"issue":"30","key":"3301_CR24","doi-asserted-by":"publisher","first-page":"49093","DOI":"10.18632\/oncotarget.17095","volume":"8","author":"J An","year":"2017","unstructured":"An J, Xu J, Li J, Jia S, Li X, Lu Y, et al. HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372. Oncotarget. 2017;8(30):49093\u2013109.","journal-title":"Oncotarget"},{"issue":"10","key":"3301_CR25","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00262-022-03167-8","volume":"71","author":"LH Qu","year":"2022","unstructured":"Qu LH, Fang Q, Yin T, Yi HM, Mei GB, Hong ZZ, et al. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71(10):2449\u201367.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"3301_CR26","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1111\/jcmm.16371","volume":"25","author":"YS Ma","year":"2021","unstructured":"Ma YS, Wu TM, Qian B, Liu YS, Ding H, Fan MM, et al. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K\/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation. J Cell Mol Med. 2021;25(8):4040\u201352.","journal-title":"J Cell Mol Med"},{"key":"3301_CR27","doi-asserted-by":"publisher","first-page":"118726","DOI":"10.1016\/j.lfs.2020.118726","volume":"264","author":"G Yan","year":"2021","unstructured":"Yan G, Li S, Yue M, Li C, Kang Z. Lysine demethylase 5B suppresses CC chemokine ligand 14 to promote progression of colorectal cancer through the Wnt\/\u03b2-catenin pathway. Life Sci. 2021;264:118726.","journal-title":"Life Sci"},{"issue":"10","key":"3301_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1452","volume":"13","author":"W Guo","year":"2023","unstructured":"Guo W, Li S, Qian Y, Li L, Wang F, Tong Y, et al. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression. Clin Transl Med. 2023;13(10):e1452.","journal-title":"Clin Transl Med"},{"issue":"14","key":"3301_CR29","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.3390\/ijms23147657","volume":"23","author":"J Lee","year":"2022","unstructured":"Lee J, Kim JS, Cho HI, Jo SR, Jang YK. JIB-04, a pan-inhibitor of histone demethylases, targets histone-lysine-demethylase-dependent akt pathway, leading to cell cycle arrest and inhibition of cancer stem-like cell properties in hepatocellular carcinoma cells. Int J Mol Sci. 2022;23(14):7657.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3301_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-025-07404-7","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, Bai J, Yuan H, Duan X, Yu L, Li Y, et al. BRD1 deficiency affects SREBF1-related lipid metabolism through regulating H3K9ac\/H3K9me3 transition to inhibit HCC progression. Cell Death Dis. 2025;16(1):1\u201314.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3301_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13148-018-0473-4","volume":"10","author":"E Cocco","year":"2018","unstructured":"Cocco E, Leo M, Canzonetta C, Di Vito S, Mai A, Rotili D, et al. KAT3B-p300 and H3AcK18\/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2. Clin Epigenetics. 2018;10(1):44.","journal-title":"Clin Epigenetics"},{"issue":"585","key":"3301_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbrc.2021.09.009","volume":"31","author":"Y Jin","year":"2021","unstructured":"Jin Y, Yang R, Ding J, Zhu F, Zhu C, Xu Q, et al. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP. Biochem Biophys Res Commun. 2021;31(585):185\u201390.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"3301_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010422","volume":"12","author":"S Liu","year":"2024","unstructured":"Liu S, Yang S, Xu M, Zhou Q, Weng J, Hu Z, et al. WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. J Immunother Cancer. 2024;12(11):e010422.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3301_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/cells8050485","volume":"8","author":"M Ha\u0142asa","year":"2019","unstructured":"Ha\u0142asa M, Wawruszak A, Przybyszewska A, Jaruga A, Guz M, Ka\u0142afut J, et al. H3K18Ac as a marker of cancer progression and potential target of anti-cancer therapy. Cells. 2019;8(5):485.","journal-title":"Cells"},{"issue":"7","key":"3301_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-05055-6","volume":"13","author":"J Wichmann","year":"2022","unstructured":"Wichmann J, Pitt C, Eccles S, Garnham AL, Li-Wai-Suen CSN, May R, et al. Loss of TIP60 (KAT5) abolishes H2AZ lysine 7 acetylation and causes p53, INK4A, and ARF-independent cell cycle arrest. Cell Death Dis. 2022;13(7):1\u201313.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3301_CR36","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1038\/s41467-024-49930-6","volume":"15","author":"S Bi","year":"2024","unstructured":"Bi S, Huang L, Chen Y, Hu Z, Li S, Wang Y, et al. KAT8-mediated H4K16ac is essential for sustaining trophoblast self-renewal and proliferation via regulating CDX2. Nat Commun. 2024;15(1):5602.","journal-title":"Nat Commun"},{"issue":"5260","key":"3301_CR37","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.272.5260.408","volume":"272","author":"J Taunton","year":"5260","unstructured":"Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 5260;272(5260):408\u201311.","journal-title":"Science"},{"issue":"10","key":"3301_CR38","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3390\/cancers11101587","volume":"11","author":"K Freese","year":"2019","unstructured":"Freese K, Seitz T, Dietrich P, Lee SML, Thasler WE, Bosserhoff A, et al. Histone deacetylase expressions in hepatocellular carcinoma and functional effects of histone deacetylase inhibitors on liver cancer cells in vitro. Cancers (Basel). 2019;11(10):1587.","journal-title":"Cancers (Basel)"},{"key":"3301_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-020-06822-4","volume":"20","author":"H Jo","year":"2020","unstructured":"Jo H, Park Y, Kim T, Kim J, Lee JS, Kim SY, et al. Modulation of SIRT3 expression through CDK4\/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells. BMC Cancer. 2020;20:332.","journal-title":"BMC Cancer"},{"issue":"2","key":"3301_CR40","first-page":"189","volume":"49","author":"Z Wang","year":"2019","unstructured":"Wang Z, Wang H, Shen P, Xie R. Expression of HDAC4 in Stage B hepatocellular carcinoma and its influence on survival. Ann Clin Lab Sci. 2019;49(2):189\u201392.","journal-title":"Ann Clin Lab Sci"},{"issue":"8","key":"3301_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-024-06981-3","volume":"15","author":"M Wang","year":"2024","unstructured":"Wang M, Liao J, Wang J, Xu M, Cheng Y, Wei L, et al. HDAC2 promotes autophagy-associated HCC malignant progression by transcriptionally activating LAPTM4B. Cell Death Dis. 2024;15(8):1\u201317.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3301_CR42","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/s12885-023-11393-1","volume":"23","author":"Y Xu","year":"2023","unstructured":"Xu Y, Zhu Y, Wu Z, Li S, Shao M, Tao Q, et al. Hepatocyte-specific HDAC3 ablation promotes hepatocellular carcinoma in females by suppressing Foxa1\/2. BMC Cancer. 2023;23(1):906.","journal-title":"BMC Cancer"},{"issue":"27","key":"3301_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40824-023-00467-7","volume":"15","author":"SM Lee","year":"2023","unstructured":"Lee SM, Cho J, Choi S, Kim DH, Ryu JW, Kim I, et al. HDAC5-mediated exosomal Maspin and miR-151a-3p as biomarkers for enhancing radiation treatment sensitivity in hepatocellular carcinoma. Biomater Res. 2023;15(27):134.","journal-title":"Biomater Res"},{"issue":"153","key":"3301_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107818","volume":"1","author":"J Peng","year":"2024","unstructured":"Peng J, Liu H, Liu Y, Liu J, Zhao Q, Liu W, et al. HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents. Bioorg Chem. 2024;1(153):107818.","journal-title":"Bioorg Chem"},{"issue":"1","key":"3301_CR45","first-page":"76","volume":"198","author":"AS Cheng","year":"2017","unstructured":"Cheng AS, Feng Y, Zhou J, Yang W, Sun H, Chen Z, et al. HDAC8 inhibition modulates liver tumor microenvironment rationale for combined epigenetic and immunotherapy. J Immunol. 2017;198(1):76\u201326.","journal-title":"J Immunol"},{"issue":"10","key":"3301_CR46","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/cancers12102734","volume":"12","author":"K Kanki","year":"2020","unstructured":"Kanki K, Watanabe R, Nguyen Thai L, Zhao CH, Naito K. HDAC9 Is preferentially expressed in dedifferentiated hepatocellular carcinoma cells and is involved in an anchorage-independent growth. Cancers. 2020;12(10):2734.","journal-title":"Cancers"},{"issue":"2","key":"3301_CR47","first-page":"503","volume":"26","author":"HN Choi","year":"2011","unstructured":"Choi HN, Bae JS, Jamiyandorj U, Noh SJ, Park HS, Jang KY, et al. Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep. 2011;26(2):503\u201310.","journal-title":"Oncol Rep"},{"issue":"6","key":"3301_CR48","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.tranon.2017.09.006","volume":"10","author":"S Huang","year":"2017","unstructured":"Huang S, Zhao Z, Tang D, Zhou Q, Li Y, Zhou L, et al. Downregulation of SIRT2 inhibits invasion of hepatocellular carcinoma by inhibiting energy metabolism. Transl Oncol. 2017;10(6):917\u201327.","journal-title":"Transl Oncol"},{"issue":"3","key":"3301_CR49","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.gendis.2020.08.007","volume":"9","author":"M Wang","year":"2022","unstructured":"Wang M, Lan L, Yang F, Jiang S, Xu H, Zhang C, et al. Hepatic SIRT6 deficit promotes liver tumorigenesis in the mice models. Genes Dis. 2022;9(3):789\u201396.","journal-title":"Genes Dis"},{"key":"3301_CR50","doi-asserted-by":"publisher","first-page":"123240","DOI":"10.1016\/j.lfs.2024.123240","volume":"359","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Liang G, Peng J, Zhang X, Yu T, et al. SIRT7 stabilizes \u03b2-catenin and promotes canonical Wnt activation via upregulating FZD7. Life Sci. 2024;359:123240.","journal-title":"Life Sci"},{"issue":"9","key":"3301_CR51","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41418-024-01342-1","volume":"31","author":"S Bian","year":"2024","unstructured":"Bian S, Ni W, Zhou L, Tong Y, Dai C, Zhao X, et al. Ubiquitin-specific protease 1 facilitates hepatocellular carcinoma progression by modulating mitochondrial fission and metabolic reprogramming via cyclin-dependent kinase 5 stabilization. Cell Death Differ. 2024;31(9):1202\u201318.","journal-title":"Cell Death Differ"},{"issue":"23","key":"3301_CR52","doi-asserted-by":"publisher","first-page":"23405","DOI":"10.1021\/acsnano.3c04636","volume":"17","author":"M Zhu","year":"2023","unstructured":"Zhu M, Fan H, Deng J, Jiang K, Liao J, Zhang X, et al. BMI1 silencing liposomes suppress postradiotherapy cancer stemness against radioresistant hepatocellular carcinoma. ACS Nano. 2023;17(23):23405\u201321.","journal-title":"ACS Nano"},{"issue":"5","key":"3301_CR53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2174\/0115665240258296231024112309","volume":"24","author":"J Xu","year":"2024","unstructured":"Xu J, Gui GSW, Yang C, Zhu S, Chen Z, Ma SLB, et al. USP3 inhibition is Active Against Chemo-resistant Hepatocellular Carcinoma Anchorage-independent Growth via Suppressing Wnt\/\u03b2-catenin. Curr Mol Med. 2024;24(5):667\u201375.","journal-title":"Curr Mol Med"},{"issue":"1","key":"3301_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13062-024-00456-3","volume":"19","author":"Q Wu","year":"2024","unstructured":"Wu Q, Qiu Y, Guo J, Yuan Z, Yang Y, Zhu Q, et al. USP40 promotes hepatocellular carcinoma cell proliferation, migration and stemness by deubiquitinating and stabilizing Claudin1. Biol Direct. 2024;19(1):13.","journal-title":"Biol Direct"},{"issue":"5","key":"3301_CR55","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/s12276-024-01223-0","volume":"56","author":"C Wang","year":"2024","unstructured":"Wang C, Ni J, Zhai D, Xu Y, Wu Z, Chen Y, et al. Stress-induced epinephrine promotes hepatocellular carcinoma progression via the USP10-PLAGL2 signaling loop. Exp Mol Med. 2024;56(5):1150\u201363.","journal-title":"Exp Mol Med"},{"key":"3301_CR56","doi-asserted-by":"crossref","unstructured":"Hu K, Li J, Yang H, Chen K, Long G, Mi X, et al. Hypoxia-induced USP13 expression drives ferroptosis resistance and tumor immune evasion in hepatocellular carcinoma through the stabilization of ACLY. Rochester, NY: Social Science Research Network. [cited 2025 Feb 19] 2025; Available from: https:\/\/papers.ssrn.com\/abstract=5114582","DOI":"10.2139\/ssrn.5114582"},{"issue":"1","key":"3301_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-024-02282-y","volume":"11","author":"R Fang","year":"2025","unstructured":"Fang R, Jia Z, Xin Y, Zhao K, Qin W, Lu H, et al. N6-methyladenosine-modification of USP15 regulates chemotherapy resistance by inhibiting LGALS3 ubiquitin-mediated degradation via AKT\/mTOR signaling activation pathway in hepatocellular carcinoma. Cell Death Discov. 2025;11(1):1\u201313.","journal-title":"Cell Death Discov"},{"issue":"1","key":"3301_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01963-5","volume":"9","author":"Q Shan","year":"2024","unstructured":"Shan Q, Yin L, Zhan Q, Yu J, Pan S, Zhuo J, et al. The p-MYH9\/USP22\/HIF-1\u03b1 axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma. Sig Transduct Target Ther. 2024;9(1):1\u201314.","journal-title":"Sig Transduct Target Ther"},{"key":"3301_CR59","doi-asserted-by":"publisher","unstructured":"Wen W, Zhou Z, Chen C, Chen M. Deubiquitinase USP28 promotes the malignant progression and radio-resistance of hepatocellular carcinoma by stabilizing WDHD1. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. [cited 2025 Feb 19] 2025; Available from: https:\/\/doi.org\/10.1007\/s00210-025-03793-w","DOI":"10.1007\/s00210-025-03793-w"},{"issue":"3","key":"3301_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.21037\/tgh.2018.04.04","volume":"23","author":"ML Tomasi","year":"2018","unstructured":"Tomasi ML, Ramani K. SUMOylation and phosphorylation cross-talk in hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2018;23(3):20.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"6","key":"3301_CR61","doi-asserted-by":"publisher","first-page":"7741","DOI":"10.1007\/s13277-015-4406-y","volume":"37","author":"W Zhang","year":"2016","unstructured":"Zhang W, Sun H, Shi X, Wang H, Cui C, Xiao F, et al. SENP1 regulates hepatocyte growth factor-induced migration and epithelial-mesenchymal transition of hepatocellular carcinoma. Tumor Biol. 2016;37(6):7741\u20138.","journal-title":"Tumor Biol"},{"issue":"1","key":"3301_CR62","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/cells10010178","volume":"10","author":"JR Ong","year":"2021","unstructured":"Ong JR, Bamodu OA, Khang NV, Lin YK, Yeh CT, Lee WH, et al. SUMO-activating enzyme subunit 1 (SAE1) Is a promising diagnostic cancer metabolism biomarker of hepatocellular carcinoma. Cells. 2021;10(1):178.","journal-title":"Cells"},{"issue":"3","key":"3301_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174374","volume":"12","author":"S Fang","year":"2017","unstructured":"Fang S, Yuan J, Shi Q, Xu T, Fu Y, Wu Z, et al. Downregulation of UBC9 promotes apoptosis of activated human LX-2 hepatic stellate cells by suppressing the canonical NF-\u03baB signaling pathway. PLoS ONE. 2017;12(3):e0174374.","journal-title":"PLoS ONE"},{"issue":"1","key":"3301_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12943-024-02030-x","volume":"23","author":"XY Zhang","year":"2024","unstructured":"Zhang XY, Li SS, Gu YR, Xiao LX, Ma XY, Chen XR, et al. CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p\/NUPR1\/FTH1 axis. Mol Cancer. 2024;23(1):113.","journal-title":"Mol Cancer"},{"issue":"22","key":"3301_CR65","doi-asserted-by":"publisher","first-page":"5700","DOI":"10.3390\/cancers13225700","volume":"13","author":"H Yuan","year":"2021","unstructured":"Yuan H, Lu Y, Chan YT, Zhang C, Wang N, Feng Y. The Role of Protein SUMOylation in human hepatocellular carcinoma: a potential target of new drug discovery and development. Cancers (Basel). 2021;13(22):5700.","journal-title":"Cancers (Basel)"},{"issue":"8026","key":"3301_CR66","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41586-024-07751-z","volume":"632","author":"HC Chen","year":"2024","unstructured":"Chen HC, He P, McDonald M, Williamson MR, Varadharajan S, Lozzi B, et al. Histone serotonylation regulates ependymoma tumorigenesis. Nat. 2024;632(8026):903\u201310.","journal-title":"Nat"},{"key":"3301_CR67","doi-asserted-by":"crossref","unstructured":"Dong R, Wang T, Dong W, Zhang H, Li Y, Tao R, et al. TGM2-mediated histone serotonylation promotes HCC progression via MYC signalling pathway. J Hepatol. [cited 2025 Mar 4] 2025; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0168827824028290","DOI":"10.1016\/j.jhep.2024.12.038"},{"key":"3301_CR68","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/blood-2024-209817","volume":"144","author":"LADA Simoes","year":"2024","unstructured":"Simoes LADA, Weinh\u00e4user I, Pereira-Martins DA, Almeida LY, Van Den Boom V, Mojallali F, et al. MLL5-driven leukemic transformation is linked to chromatin remodeling and can be targeted with ATRA in combination with PARP1 inhibition. Blood. 2024;144:1539.","journal-title":"Blood"},{"issue":"1","key":"3301_CR69","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/ijo.2014.2423","volume":"45","author":"FT Hsu","year":"2014","unstructured":"Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, et al. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK\/NF-\u03baB signaling. Int J Oncol. 2014;45(1):177\u201388.","journal-title":"Int J Oncol"},{"issue":"1","key":"3301_CR70","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s13046-024-03221-6","volume":"43","author":"S Demir","year":"2024","unstructured":"Demir S, Hotes A, Schmid T, Cairo S, Indersie E, Pisano C, et al. Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma. J Exp Clin Cancer Res. 2024;43(1):299.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3301_CR71","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/fcp.12608","volume":"35","author":"X Yang","year":"2021","unstructured":"Yang X, Liu J, Liang Q, Sun G. Valproic acid reverses sorafenib resistance through inhibiting activated Notch\/Akt signaling pathway in hepatocellular carcinoma. Fundam Clin Pharmacol. 2021;35(4):690\u20139.","journal-title":"Fundam Clin Pharmacol"},{"issue":"10","key":"3301_CR72","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1111\/jcmm.17322","volume":"26","author":"Q Yu","year":"2022","unstructured":"Yu Q, Dai W, Ji J, Wu L, Feng J, Li J, et al. Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc\/hexokinase 2 pathway. J Cell Mol Med. 2022;26(10):3031\u201345.","journal-title":"J Cell Mol Med"},{"key":"3301_CR73","unstructured":"HDAC6 promote HCCLM3 cell migration and invasion by regulating TGF-\u03b21 pathway | bioRxiv. [cited 2025 Dec 18]. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.02.23.432488v1.abstract"},{"issue":"13","key":"3301_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33740","volume":"10","author":"S Fu","year":"2024","unstructured":"Fu S, Xu M, Li J, Yu M, Wang S, Han L, et al. HDAC6 inhibitor ACY-1215 protects from nonalcoholic fatty liver disease via inhibiting CD14\/TLR4\/MyD88\/MAPK\/NF\u03baB signal pathway. Heliyon. 2024;10(13):e33740.","journal-title":"Heliyon"},{"issue":"11","key":"3301_CR75","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/ph17111467","volume":"17","author":"EN Seane","year":"2024","unstructured":"Seane EN, Nair S, Vandevoorde C, Bisio A, Joubert A. Multi-Target Inhibitor CUDC-101 Impairs DNA Damage Repair and Enhances Radiation Response in Triple-Negative Breast Cell Line. Pharmaceuticals (Basel). 2024;17(11):1467.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"13","key":"3301_CR76","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.7150\/ijbs.27661","volume":"14","author":"B He","year":"2018","unstructured":"He B, Dai L, Zhang X, Chen D, Wu J, Feng X, et al. The HDAC inhibitor Quisinostat (JNJ-26481585) supresses hepatocellular carcinoma alone and synergistically in combination with sorafenib by G0\/G1 phase arrest and apoptosis induction. Int J Biol Sci. 2018;14(13):1845\u201358.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"3301_CR77","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180360","volume":"38","author":"L Liu","year":"2018","unstructured":"Liu L, Sun X, Xie Y, Zhuang Y, Yao R, Xu K. Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma. Biosci Rep. 2018;38(4):BSR20180360.","journal-title":"Biosci Rep"},{"key":"3301_CR78","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02703-7","author":"T Takamoto","year":"2025","unstructured":"Takamoto T, Mihara Y, Nishioka Y, Ichida A, Kawaguchi Y, Akamatsu N, et al. Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies. Int J Clin Oncol. 2025. https:\/\/doi.org\/10.1007\/s10147-025-02703-7.","journal-title":"Int J Clin Oncol"},{"key":"3301_CR79","doi-asserted-by":"publisher","first-page":"11725","DOI":"10.2147\/OTT.S279858","volume":"13","author":"T Cui","year":"2020","unstructured":"Cui T, Liu Y, Wang J, Liu L. Adverse effects of immune-checkpoint inhibitors in hepatocellular carcinoma. Onco Targets Ther. 2020;13:11725\u201340.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"3301_CR80","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41598-024-84304-4","volume":"15","author":"S Cherradi","year":"2025","unstructured":"Cherradi S, Roux S, Dupuy M, Tabone-Eglinger S, Tuaillon E, Ziol M, et al. Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy. Sci Rep. 2025;15(1):1179.","journal-title":"Sci Rep"},{"issue":"1","key":"3301_CR81","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12935-023-03051-0","volume":"23","author":"R Han","year":"2023","unstructured":"Han R, Ling C, Wang Y, Lu L. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1\/PD-L1 inhibition. Cancer Cell Int. 2023;23(1):203.","journal-title":"Cancer Cell Int"},{"key":"3301_CR82","first-page":"101425","volume":"55","author":"S Chan","year":"2025","unstructured":"Chan S, Cheng A, La Thangue N, Kerr D. Epigenetic therapeutics to overcome resistance against immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC): a proof-of-concept clinical trial. Lancet Reg Health West Pac. 2025;55:101425.","journal-title":"Lancet Reg Health West Pac"},{"key":"3301_CR83","doi-asserted-by":"publisher","first-page":"117185","DOI":"10.1016\/j.ejmech.2024.117185","volume":"283","author":"Z Lv","year":"2025","unstructured":"Lv Z, Ji T, Liu J, Sun X, Liang H. Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: A review. Eur J Med Chem. 2025;283:117185.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3301_CR84","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/radiation2010011","volume":"2","author":"J Antrobus","year":"2022","unstructured":"Antrobus J, Parsons JL. Histone deacetylases and their potential as targets to enhance tumour radiosensitisation. Radiat. 2022;2(1):149\u201367.","journal-title":"Radiat"},{"issue":"8","key":"3301_CR85","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.7150\/ijbs.93375","volume":"20","author":"S Yan","year":"2024","unstructured":"Yan S, Chen L, Zhuang H, Yang H, Yang Y, Zhang N, et al. HDAC Inhibition sensitize hepatocellular carcinoma to lenvatinib via suppressing AKT activation. Int J Biol Sci. 2024;20(8):3046\u201360.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3301_CR86","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1570159X13666151021111609","volume":"14","author":"S Ahmad Ganai","year":"2016","unstructured":"Ahmad Ganai S, Ramadoss M, Mahadevan V. Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration. Curr Neuropharmacol. 2016;14(1):55\u201371.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"3301_CR87","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40001-025-02326-8","volume":"30","author":"W Zhang","year":"2025","unstructured":"Zhang W, Ge L, Zhang Y, Zhang Z, Zhang W, Song F, et al. Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies. Eur J Med Res. 2025;30(1):69.","journal-title":"Eur J Med Res"},{"issue":"1","key":"3301_CR88","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12935-024-03450-x","volume":"24","author":"P Nakka","year":"2024","unstructured":"Nakka P, Jassi C, Chen MC, Liu YS, Liu JY, Yeh CM, et al. Sensitization of hepatocellular carcinoma cells to HDACi is regulated through hsa-miR-342-5p\/CFL1. Cancer Cell Int. 2024;24(1):291.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"3301_CR89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"Shi MQ, Xu Y, Fu X, Pan DS, Lu XP, Xiao Y, et al. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol Oncol. 2024;17(1):37.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3301_CR90","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4251\/wjgo.v14.i1.75","volume":"14","author":"HY Sun","year":"2022","unstructured":"Sun HY, Du ST, Li YY, Deng GT, Zeng FR. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. World J Gastrointest Oncol. 2022;14(1):75\u201389.","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"3301_CR91","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","volume":"79","author":"AD Ladd","year":"2024","unstructured":"Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatol. 2024;79(4):926.","journal-title":"Hepatol"},{"issue":"63","key":"3301_CR92","doi-asserted-by":"publisher","first-page":"106833","DOI":"10.18632\/oncotarget.21880","volume":"8","author":"HP Zhang","year":"2017","unstructured":"Zhang HP, Li GQ, Guo WZ, Chen GH, Tang HW, Yan B, et al. Oridonin synergistically enhances JQ1-triggered apoptosis in hepatocellular cancer cells through mitochondrial pathway. Oncotarget. 2017;8(63):106833\u201343.","journal-title":"Oncotarget"},{"issue":"10","key":"3301_CR93","doi-asserted-by":"publisher","first-page":"506","DOI":"10.5483\/BMBRep.2022.55.10.037","volume":"55","author":"B Moon","year":"2022","unstructured":"Moon B, Park M, Cho SH, Kim KM, Seo HR, Kim JH, et al. Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells. BMB Rep. 2022;55(10):506\u201311.","journal-title":"BMB Rep"},{"key":"3301_CR94","unstructured":"Thng DKH, Toh TB, Pigini P, Hooi L, Dan YY, Chow PKH, et al. Splice\u2010switch oligonucleotide\u2010based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC\u2010driven hepatocellular carcinoma. 2025; https:\/\/aiche.onlinelibrary.wiley.com\/doi\/10.1002\/btm2.10363"},{"issue":"4","key":"3301_CR95","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/08853282231202326","volume":"38","author":"W Gao","year":"2023","unstructured":"Gao W, Shen R. Nanogel enhances the efficacy of MLN8237 in treating hepatocellular carcinoma. J Biomater Appl. 2023;38(4):527\u201337.","journal-title":"J Biomater Appl"},{"issue":"20","key":"3301_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38562","volume":"10","author":"X Zhou","year":"2024","unstructured":"Zhou X, Man M, Cui M, Zhou X, Hu Y, Liu Q, et al. Relationship between EZH2 expression and prognosis of patients with hepatocellular carcinoma using a pathomics predictive model. Heliyon. 2024;10(20):e38562.","journal-title":"Heliyon"},{"issue":"1","key":"3301_CR97","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13046-023-02659-4","volume":"42","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang Y, Cao J, Su Z, Li F, Zhang P, et al. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. J Exp Clin Cancer Res. 2023;42(1):96.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3301_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-025-07359-9","volume":"16","author":"Y Zeng","year":"2025","unstructured":"Zeng Y, Jiang H, Chen Z, Xu J, Zhang X, Cai W, et al. Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN. Cell Death Dis. 2025;16(1):1\u201316.","journal-title":"Cell Death Dis"},{"issue":"9","key":"3301_CR99","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12032-025-02941-9","volume":"42","author":"A Schcolnik-Cabrera","year":"2025","unstructured":"Schcolnik-Cabrera A, Ram\u00edrez-Yautentzi M, Soria-Castro R, Chac\u00f3n-Salinas R, Morales-B\u00e1rcenas R, Dom\u00ednguez-G\u00f3mez G, et al. Epigenetic reprogramming of mast and cancer cells modifies tumor-promoting cytokine networks. Med Oncol. 2025;42(9):371.","journal-title":"Med Oncol"},{"issue":"2","key":"3301_CR100","first-page":"5","volume":"8","author":"A Schcolnik-Cabrera","year":"2018","unstructured":"Schcolnik-Cabrera A, Dom\u00ednguez-G\u00f3mez G, Due\u00f1as-Gonz\u00e1lez A. Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells. Am J Blood Res. 2018;8(2):5\u201316.","journal-title":"Am J Blood Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03301-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03301-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03301-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:01:50Z","timestamp":1785128510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03301-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":100,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["3301"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03301-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"203"}}